(E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-methylbenzamide hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-methylbenzamide hydrochloride
• 英文别名: 4-[(E)-2-(aminomethyl)-3-fluoroprop-2-enoxy]-N-methylbenzamide;hydrochloride
• 化学式: C₁₂H₁₅FN₂O₂*ClH
• 分子量: 274.723
• InChiKey: RWELQWORXMDUNI-MLBSPLJJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF<br/>[FR] INHIBITEURS DE SSAO 3-HALOGÉNOALLYLAMINES SUBSTITUÉES ET LEURS UTILISATIONS
  申请人：PHARMAXIS LTD

  公开号：WO2013163675A1

  公开（公告）日：2013-11-07

  The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula (I), as defined in the specification. The invention also relates to methods of using compounds of Formula (I), or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

  本发明涉及取代3-卤丙烯胺衍生物的制备和药用，其作为具有式（I）中定义的SSAO/VAP-1抑制剂。该发明还涉及使用式（I）化合物或其药用盐或衍生物的方法，用于治疗各种适应症，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病诱导疾病和癌症。
• SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF
  申请人：Pharmaxis Ltd.

  公开号：US20150158813A1

  公开（公告）日：2015-06-11

  The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.

  本文描述了替代的3-卤代烯丙胺衍生物的制备和制药用途，作为具有公式I结构的SSAO/VAP-1抑制剂。还描述了使用公式I化合物或其药学上可接受的盐或衍生物治疗各种疾病的方法，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病诱导的疾病和癌症。
• Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160244406A1

  公开（公告）日：2016-08-25

  The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

  本发明涉及制备和药物应用具有式I结构的取代3-卤代烯丙胺衍生物作为SSAO/VAP-1抑制剂。该式在说明书中定义。本发明还涉及使用式I化合物或其药学上可接受的盐或衍生物的方法，用于治疗各种疾病，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病引起的疾病和癌症。
• Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10160723B2

  公开（公告）日：2018-12-25

  The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

  本发明涉及具有如说明书中定义的式 I 结构的取代 3-卤代烯丙胺衍生物作为 SSAO/VAP-1 抑制剂的制备和药物用途： 本发明还涉及使用式 I 化合物或其药学上可接受的盐或衍生物治疗各种适应症的方法，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病引起的疾病和癌症。
• SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF
  申请人：PharmAxis Ltd

  公开号：EP2844637A1

  公开（公告）日：2015-03-11